T&R Biofab said Thursday that it has obtained sales approval from the Thailand government for T&R Mesh, its 3D printing medical device. The device can print out 18 different biodegradable biomaterial implant models that can either regenerate or reconstruct defects due to trauma or craniomaxillofacial reconstructive surgery and is easy to shape during operation while having few side effects. The sales approval in Thailand came after the company got a regulatory nod for the same device in Vietnam in January. T&R Biofab plans to speed up marketing in Southeast Asia following the go-ahead from the two nations. T&R Biofab is trying to sign a contract with a Thai medical device company and plans to launch the products in the market from the second half of this year after finalizing the negotiation. “Following the acquisition of a license in Vietnam and Thailand, the company expects to accelerate the expansion of its 3D printing medical device in the related markets,” a company official said. “Thailand is the second-largest market for medical technology in the ASEAN market, followed by Singapore while having the eighth largest medical device market in the Asia-Pacific region.” T&R Biofab expects rapid growth and stable sales in the future, he added. tweet Lee Han-soo corea022@docdocdoc.co.kr See Other Articles Copyright © KBR Unauthorized reproduction, redistribution prohibited News That You Haven't Seen Polycythemia vera moves a step closer to potential cure ‘Aggressive interferon treatment needed to reach MRD in myeloproliferative neoplasms’ Generative AI, top investment priority for 62% of healthcare CEOs: KHIDI report Handok and Swedish Orphan Biovitrum launch joint venture in Korea [Column] Why eating microplastics is harmful Samsung Bioepis secures 1st approval in Korea for Stelara biosimilar ‘Goal of treating hemophilia is to normalize life like a non-patient’ Polycythemia vera moves a step closer to potential cure Comments Log In 작성자 비밀번호 댓글 내용입력 댓글 정렬 Newest Recommended Top Comments BEST Comments BEST Comments It is automatically exposed by adding up the number of replies and recommendations. 닫기 More Delete comments Deleted comments cannot be recovered. Do you still want to delete it? Password 닫기 Modify the comments You can modify comments only within 1 minute after writing. Text / 400 Password 닫기 My comment collection 닫기 Important News Samsung Biologics' Q1 sales, operating income hit record high Celltrion-incubated startups move into Seoul Biohub Hemorrhagic cystitis could occur in prostate cancer patients 1 year after radiotherapy. Why? LG Chem partners with EuBiologics to develop pediatric vaccine against 6 diseases Entresto builds clinical evidence for 'heart failure with ejection fraction rate exceeding 40%’ University hospitals in crisis: senior doctors resign amid burnout, financial woes deepen
T&R Biofab said Thursday that it has obtained sales approval from the Thailand government for T&R Mesh, its 3D printing medical device. The device can print out 18 different biodegradable biomaterial implant models that can either regenerate or reconstruct defects due to trauma or craniomaxillofacial reconstructive surgery and is easy to shape during operation while having few side effects. The sales approval in Thailand came after the company got a regulatory nod for the same device in Vietnam in January. T&R Biofab plans to speed up marketing in Southeast Asia following the go-ahead from the two nations. T&R Biofab is trying to sign a contract with a Thai medical device company and plans to launch the products in the market from the second half of this year after finalizing the negotiation. “Following the acquisition of a license in Vietnam and Thailand, the company expects to accelerate the expansion of its 3D printing medical device in the related markets,” a company official said. “Thailand is the second-largest market for medical technology in the ASEAN market, followed by Singapore while having the eighth largest medical device market in the Asia-Pacific region.” T&R Biofab expects rapid growth and stable sales in the future, he added.
News That You Haven't Seen Polycythemia vera moves a step closer to potential cure ‘Aggressive interferon treatment needed to reach MRD in myeloproliferative neoplasms’ Generative AI, top investment priority for 62% of healthcare CEOs: KHIDI report Handok and Swedish Orphan Biovitrum launch joint venture in Korea [Column] Why eating microplastics is harmful Samsung Bioepis secures 1st approval in Korea for Stelara biosimilar ‘Goal of treating hemophilia is to normalize life like a non-patient’
Comments Log In 작성자 비밀번호 댓글 내용입력 댓글 정렬 Newest Recommended Top Comments BEST Comments BEST Comments It is automatically exposed by adding up the number of replies and recommendations. 닫기 More
댓글 정렬 Newest Recommended Top Comments BEST Comments BEST Comments It is automatically exposed by adding up the number of replies and recommendations. 닫기 More
Important News Samsung Biologics' Q1 sales, operating income hit record high Celltrion-incubated startups move into Seoul Biohub Hemorrhagic cystitis could occur in prostate cancer patients 1 year after radiotherapy. Why? LG Chem partners with EuBiologics to develop pediatric vaccine against 6 diseases Entresto builds clinical evidence for 'heart failure with ejection fraction rate exceeding 40%’ University hospitals in crisis: senior doctors resign amid burnout, financial woes deepen